Changed dynamics in the insulin market mean Novo Nordisk and Eli Lilly are not as invincibleas in the past, says a director from Adocia. The French biotech company aims to take on the giants - and also compete with Zealand Pharma in another segment of the diabetes market.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.